# Remimazolam Versus Midaszolam for Sedation in Diagnostic Upper Gastrointestinal Endoscopy

> **NCT05836545** · PHASE3 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 132 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Remimazolam
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT05836545
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-05
- **Primary completion:** 2024-01-06
- **Final completion:** 2024-01-06
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05836545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05836545, "Remimazolam Versus Midaszolam for Sedation in Diagnostic Upper Gastrointestinal Endoscopy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05836545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*